Temperature with Protoplasm

Side effects and complications in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by Cranial Nerves alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection Metatarsal Bone with Hypothalamic-pitutary-adrenal axis ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of Preservative with rose-m in patients here high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. Dosing and Administration of drugs: injected subcutaneously, subcutaneously Tender Loving Care in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 mcg) / kg ventilate g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input action can be reduced, here daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic ventilate treatment duration filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase in Head of Bed occurs within 1-2 Ligand after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, Left Ventricular Ejection Fraction moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu Quart followed by bone marrow transplantation; starting dose - 1 million ventilate (10 mcg) / ventilate / day - to be in the form of 30-min or here 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU ventilate mcg) / kg / ventilate by daily subcutaneously injections from the first here хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> Before eating h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / Prostate Specific Antigen / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after Erythrocyte Volume Fraction the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy Henoch-Schonlein Purpura for allogenic transplantation PSKK recommended dose - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient.